8 results about "Anticoagulant activity" patented technology

This invention relates to the field of biomedicine, and particularly to a hirudin gene, expression vector, engineered bacteria, recombinant protein, and its applications and production methods, all possessing anticoagulant, thrombolytic, and antioxidant effects. The nucleotide sequence of the hirudin gene is shown in SEQ ID NO: 1. The amino acid sequence of the recombinant protein is shown in SEQ ID NO: 2. The recombinant protein of the hirudin gene provided by this invention, possessing anticoagulant, thrombolytic, and antioxidant effects, exhibits a high concentration of recombinant hirudin, significantly increasing the yield of recombinant hirudin. The recombinant hirudin also demonstrates strong in vitro anticoagulant and thrombolytic activity, indicating broad market prospects.

This application discloses a complex polysaccharide, its preparation method, and its applications. It discloses both a novel use of sulfated kudzu polysaccharide as a raw material for preparing drugs with anticoagulant effects and a complex polysaccharide comprising sulfated polysaccharide and polysaccharide fragments; wherein the sulfated polysaccharide includes sulfated kudzu polysaccharide and / or sulfated Bletilla striata polysaccharide; and the polysaccharide fragments include glycosaminoglycan fragments. This application modifies the structure of natural polysaccharides to improve their structural properties, preparing and screening complex polysaccharides with anticoagulant activity. The components in the complex polysaccharide work synergistically, significantly enhancing the anticoagulant effect and broadening the application fields of polysaccharides, primarily for the development of anticoagulant drugs and anticoagulant medical devices.

This invention discloses an earthworm protein peptide with in vitro thrombin-inhibiting activity and its preparation method, belonging to the field of functional food technology. The method first pre-treats earthworm raw materials to obtain earthworm protein; then, it uses pepsin and alkaline protease for stepwise enzymatic hydrolysis under varying temperature and pH, and ultrafiltration to collect short peptide solutions with a molecular weight below 3 kDa; the short peptide solution is specifically captured using an affinity chromatography material coupled with bovine thrombin, followed by elution, nanofiltration desalting concentration, and spray drying to obtain the final product. This invention fully releases the peptides through a dual enzymatic hydrolysis process and utilizes thrombin affinity chromatography to directionally enrich peptides with specific inhibitory activity, effectively solving the problems of low content and poor targeting of active ingredients in earthworm protein peptides in existing technologies, and significantly improving the purity and in vitro anticoagulant activity of the product.

This invention provides a sheep milk casein anticoagulant peptide, its preparation method, and its applications. The sheep milk casein inhibitory peptide is VKETMVPK, VLPVPQK, or EMPFPK. This invention addresses the problems of low safety and high cost of existing clinical anticoagulant drugs, and the low utilization rate of high-value sheep milk casein resources. It fills the technological gap in the preparation of sheep milk casein anticoagulant peptides. The provided sheep milk casein inhibitory peptide has high safety, avoiding the drawbacks of existing drug treatments; efficiently taps the value of sheep milk resources, reducing resource waste; fills a technological gap, establishing a systematic preparation system; has clear and efficient anticoagulant activity with a comprehensive mechanism of action; and has wide applications and great market potential.

This invention discloses a high-yield, dual-effect earthworm protein small molecule peptide and its preparation method, specifically relating to the field of biomedical technology. The preparation method includes: S1, synergistic enzymatic hydrolysis: earthworm protein undergoes autolysis, followed by enzymatic hydrolysis with a complex enzyme of flavor protease and alkaline protease; S2, charge-size bi-stage membrane separation: the hydrolysate is sequentially passed through a 5kDa first-stage ultrafiltration membrane and a 1kDa second-stage ultrafiltration membrane modified with a positive charge; S3, dual-activity-guided purification: using anticoagulant activity and dipeptidyl peptidase-IV inhibitory activity as tracking indicators, the highly active components are collected. The small molecule peptide obtained by this invention has a molecular weight of 400-800 Da, contains novel sequences shown in SEQ ID NO:1 and SEQ ID NO:2, and simultaneously possesses anticoagulant activity and DPP-IV inhibitory activity, with a yield of 17.2-19.1%, which is more than 30% higher than conventional methods. The process of this invention is stable and has good prospects for industrialization.

An anticoagulant phenyl-linked heparin oligosaccharide dimer, a preparation method therefor and use thereof are provided. The anticoagulant phenyl-linked heparin oligosaccharide dimer has a structure as represented by general formula I, and the phenyl may be replaced with substituted phenyl, heteroaryl or substituted heteroaryl. The described phenyl-linked heparin oligosaccharide dimer may be synthesized in fewer steps, has a significantly higher total yield, potent and specific antithrombin-dependent anti-Factor Xa activity without significant anti-FactorIIa activity, the anticoagulant activity may be efficiently neutralized by protamine sulfate, has excellent pharmacokinetic profiles, making it suitable for the preparation of novel anticoagulant and antithrombotic drugs that are cost-effective, higher-quality and safer.

This invention discloses a fibrinolytic enzyme-producing Pseudomonas hygroscopicus originating from mangrove wetlands (… Fictibacillus rigui The strain QMS71 is deposited at the China General Microbiological Culture Collection Center (CGMCC) under accession number CGMCC No. 37018. Under suitable culture conditions, strain QMS71 can produce extracellular enzymes with fibrin-degrading activity. Its fermentation products exhibit significant fibrin degradation activity in vitro and demonstrate thrombolytic and anticoagulant activities in relevant in vitro functional evaluation models. This invention provides a well-identified fibrinolytic enzyme-producing microbial resource and its applications, which can be used for in vitro functional evaluation, model studies, and functional enzymology research related to fibrin degradation.

The invention belongs to the technical field of biological medicine, and particularly relates to earthworm anticoagulant oligopeptide and application thereof. The invention relates to an anticoagulant oligopeptide, which is found by combining the activity-directed separation of pheretima asper (E. Perriver) with the screening of an AI (artificial intelligence) prediction model. The amino acid sequence of the oligopeptide is LMWFSDRNK; the oligopeptide regulates thrombin in an allosteric manner, enhances the combination of thrombin and antithrombin, and can effectively inhibit blood coagulation and thrombus formation at in-vivo and in-vitro levels; the oligopeptide has a remarkable anticoagulant effect and is suitable for research and development of antithrombotic drugs.